Bromide

Bromide

SCHEMBL26094983

Br.Oc1ccc(-c2cc(-c3ccc(O)c(O)c3)on2)cc1O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B1 P14061 1/20 0.54
▸ HSD17B2 P37059 1/20 0.54
▸ NPC1 O15118 6/20 0.48
▸ RAB9A P51151 6/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ HPGD P15428 3/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ APP P05067 1/20 0.46
▸ SNCA P37840 5/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ POLB P06746 2/20 0.45
▸ GAA P10253 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15425104 0.98 HSD17B1 (0.56) HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2
SCHEMBL1661039 0.89 HSD17B1 (0.69) HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2
SCHEMBL1662253 0.85 HSD17B1 (0.55) HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2
SCHEMBL31660479 0.85 HSD17B1 (0.55) HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2
SCHEMBL23558362 0.76 MAPT (0.51) HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2
SCHEMBL1180676 0.75 HSD17B1 (0.74) HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2
SCHEMBL5728908 0.74 HSD17B1 (0.84) HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2
Bromide SCHEMBL1660283 0.70 S1PR1 (0.54) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL21446983 0.70 ROCK2 (0.59) NPC1RAB9ASMN1; SMN2HPGDMEN1
SCHEMBL1179871 0.70 HSD17B1 (1.00) HSD17B1HSD17B2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250228242-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-07-17 — — US claimed
EP-4173485-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-03 — — EP claimed
US-20250228242-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-07-17 — — US disclosed
EP-4173485-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250228242-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL APP, APBA1, PRNP HSD17B1 3779/4885HSD17B2 4435/4885NPC1 2456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback